Actual pentamidine dose delivered by Respigard II nebulizer

C. S. Kim, L. Garcia, A. Wanner

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The Respigard II nebulizer system is the approved method to deliver pentamidine aerosols in the USA. Although continuous operation of the nebulizer until dryness is a designated regimen, the actual pentamidine dose delivered under the operating condition has not been thoroughly studied. Pentamidine solutions (300 mg in 6 mL water) were nebulized continuously with the Respigard II nebulizer system until dryness (40 min operation). Aerosols were delivered to the lower airways via an oropharyngeal model and sampled on a filter with a standard breathing mode of 20 breaths·min-1 frequency and 750 mL tidal volume. Intermediate samples were also obtained for the initial 20 min delivery. The pentamidine dose delivered to the mouth was 1.6% of the dose placed in the nebulizer. Of the dose delivered to the mouth, 92% was delivered during the initial 20 min period. Aerosol loss in the oropharyngeal model was 15% of the dose delivered to the mouth or 0.24% of the dose initially placed in the nebulizer. Pentamidine dose delivered to the lower airways was a very small fraction of the initial dose in the nebulizer. A partial delivery for the initial 20 min was nearly comparable to complete delivery.

Original languageEnglish (US)
Pages (from-to)2178-2181
Number of pages4
JournalEuropean Respiratory Journal
Volume8
Issue number12
DOIs
StatePublished - Dec 29 1995
Externally publishedYes

Keywords

  • aerosol delivery
  • nebulizer
  • pentamidine

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Actual pentamidine dose delivered by Respigard II nebulizer'. Together they form a unique fingerprint.

  • Cite this